Pseudomembranous colitis is most commonly associated with which drug class?
A 45-year-old female is diagnosed with pneumococcal meningitis. While awaiting culture sensitivity results, what is the best empirical treatment to start?
Which of the following drug classes is known to cause nephrotoxicity?
What is the treatment of choice for benign tertian malaria?
All of the following drugs can be used for the management of malaria due to chloroquine-resistant vivax except?
The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivatives (artemisinin-based combination therapies or ACTs). Which of the following combination therapies is NOT recommended if such resistance is suspected?
Antibiotic prophylaxis is not recommended in which of the following procedures?
Eirenz is used for the treatment of HIV infections. How does it act?
Which of the following drugs shows a disulfiram-like reaction with alcohol?
Which drug is used in the management of steroid-resistant lepra reactions?
Explanation: **Explanation:** Pseudomembranous colitis (PMC) is caused by the overgrowth of *Clostridioides difficile* following the suppression of normal gut flora by broad-spectrum antibiotics. **Why Penicillins are the correct answer:** While **Clindamycin** is classically cited as having the *highest relative risk* per dose, **Amoxicillin and Ampicillin** (broad-spectrum Penicillins) are the **most common causes** in clinical practice due to their high frequency of prescription. In the context of NEET-PG, when asked for the most common association, broad-spectrum Penicillins (often in combination with Cephalosporins) are the leading culprits due to sheer volume of use. **Analysis of Incorrect Options:** * **Macrolides (A):** While drugs like Erythromycin can cause diarrhea (via motilin receptor agonism), they are less frequently associated with *C. difficile* compared to Penicillins. * **Glycopeptides (C):** **Vancomycin** (a glycopeptide) is actually a **treatment** for PMC when administered orally, as it is not absorbed and acts directly on *C. difficile* in the gut. * **Fluoroquinolones (D):** These are a significant cause of PMC outbreaks (especially the NAP1/BI/027 strain), but statistically, they still trail behind the combined group of Penicillins and Cephalosporins in total case numbers. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Oral **Vancomycin** or **Fidaxomicin** are first-line treatments. Metronidazole is now reserved for non-severe cases if other options are unavailable. * **Pathogenesis:** Mediated by **Toxin A (Enterotoxin)** and **Toxin B (Cytotoxin)**. * **Diagnosis:** Detection of toxins in stool or visualization of "yellowish-white plaques" (pseudomembranes) on sigmoidoscopy. * **Classic "Buzzword" Association:** Clindamycin (highest risk); Penicillins/Cephalosporins (most common).
Explanation: **Explanation:** The empirical treatment of bacterial meningitis must cover the most likely pathogens (*Streptococcus pneumoniae*, *Neisseria meningitidis*) and account for increasing patterns of drug resistance. **Why Option D is Correct:** * **Ceftriaxone (3rd Gen Cephalosporin):** This is the backbone of therapy due to its excellent CSF penetration and broad-spectrum activity against common meningeal pathogens. * **Vancomycin:** Due to the rising prevalence of **Penicillin-resistant *Streptococcus pneumoniae* (PRSP)** and emerging resistance to cephalosporins, Vancomycin is added empirically. It ensures coverage against highly resistant strains until specific sensitivities are available. **Why Other Options are Incorrect:** * **A. Penicillin G:** While historically the drug of choice, it is no longer used empirically due to widespread high-level resistance in *S. pneumoniae*. * **B. Doxycycline:** This is a bacteriostatic drug with poor CSF penetration; it is not indicated for acute bacterial meningitis. * **C. Streptomycin:** This aminoglycoside has negligible CSF penetration and is primarily used for Tuberculosis or Plague, not for acute pyogenic meningitis. **High-Yield Clinical Pearls for NEET-PG:** 1. **Steroid Adjunct:** Dexamethasone should be administered **before or with the first dose** of antibiotics to reduce neurological complications (like hearing loss) caused by the inflammatory response to bacterial lysis. 2. **Age-Specific Coverage:** In patients >50 years or those who are immunocompromised, **Ampicillin** must be added to the regimen to cover *Listeria monocytogenes*. 3. **Prophylaxis:** Rifampicin is the drug of choice for chemoprophylaxis in close contacts of *N. meningitidis* or *H. influenzae* meningitis.
Explanation: **Explanation:** **Aminoglycosides (Option B)** are the correct answer as they are notoriously associated with **dose-dependent nephrotoxicity**. The underlying mechanism involves the accumulation of the drug within the proximal convoluted tubule (PCT) cells. Aminoglycosides are filtered by the glomerulus and then reabsorbed by the tubular epithelium via the megalin-cubilin transport system. Once inside, they cause lysosomal rupture and oxidative stress, leading to **Acute Tubular Necrosis (ATN)**. This is typically reversible upon discontinuation of the drug. **Why other options are incorrect:** * **Doxycycline (Option A):** Unlike other tetracyclines, doxycycline is primarily excreted via the biliary route (feces), making it the safest tetracycline in patients with renal failure. It does not cause nephrotoxicity. * **Erythromycin (Option B):** This macrolide is primarily metabolized by the liver and excreted in bile. Its chief side effects are GI upset (motilin receptor agonism) and cholestatic hepatitis, not renal damage. * **Rifampicin (Option D):** While it can rarely cause interstitial nephritis, its hallmark side effects are hepatotoxicity and the harmless orange-red discoloration of body fluids. **High-Yield Clinical Pearls for NEET-PG:** 1. **Nephrotoxicity vs. Ototoxicity:** Aminoglycosides cause both. Neomycin is the most nephrotoxic; Streptomycin is the least. 2. **Monitoring:** To minimize toxicity, **Once-Daily Dosing** (Extended Interval Dosing) is preferred due to the "Post-Antibiotic Effect." 3. **Drug Interactions:** Risk of nephrotoxicity increases when aminoglycosides are co-administered with Loop Diuretics (e.g., Furosemide), Vancomycin, or Cisplatin. 4. **Rule of Thumb:** Aminoglycosides are "Mean" (NEphrotoxic and Ototoxic).
Explanation: **Explanation:** **Benign tertian malaria** is caused by *Plasmodium vivax* and *Plasmodium ovale*. The standard treatment of choice for these species remains **Chloroquine**, as it is highly effective against the erythrocytic stages of the parasite in most regions. 1. **Why Chloroquine is Correct:** Chloroquine is a 4-aminoquinoline that concentrates in the acidic food vacuole of the parasite, inhibiting heme polymerase. This leads to the accumulation of toxic heme, killing the parasite. For *P. vivax* and *P. ovale*, it rapidly clears the fever and parasitemia. 2. **Why other options are incorrect:** * **Sulfamethoxazole-pyrimethamine (Option A):** Primarily used for chloroquine-resistant *P. falciparum*. It is not the first-line agent for benign tertian malaria due to slower action and increasing resistance. * **Quinine (Option B):** Reserved for severe or complicated malaria and chloroquine-resistant cases. It has a narrow therapeutic index and significant side effects (Cinchonism). * **Mefloquine (Option C):** Used for prophylaxis in travelers or as a second-line treatment for resistant *P. falciparum*. It is associated with neuropsychiatric side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Radical Cure:** Chloroquine only treats the blood stages. To prevent relapse from dormant liver stages (**hypnozoites**), **Primaquine** must be administered for 14 days. * **G6PD Screening:** Always screen for G6PD deficiency before starting Primaquine to avoid acute hemolysis. * **Drug of Choice for Pregnancy:** Chloroquine is safe and remains the drug of choice for malaria in pregnancy (all trimesters) for sensitive strains. * **Malignant Tertian Malaria:** Refers to *P. falciparum*, which is typically treated with ACT (Artemisinin-based Combination Therapy).
Explanation: **Explanation:** The management of chloroquine-resistant *Plasmodium vivax* (CRPV) has become a clinical challenge in certain endemic regions (e.g., Indonesia, parts of India). According to WHO and National Guidelines, the treatment strategy for CRPV mirrors that of *P. falciparum*. **Why Fluoroquinolones are the Correct Answer:** While some fluoroquinolones (like Ciprofloxacin or Levofloxacin) exhibit weak anti-plasmodial activity *in vitro*, they are **not clinically recommended** or effective for the management of malaria. They lack the potency required to clear parasites effectively and are never used as standard therapy for any form of malaria. **Analysis of Other Options:** * **Artesunate (Option C):** ACT (Artemisinin-based Combination Therapy) is the current **first-line treatment** for chloroquine-resistant malaria (both *falciparum* and *vivax*). * **Quinine (Option A):** Historically the mainstay for resistant malaria, it remains an effective alternative, especially in severe cases or when ACTs are unavailable. * **Doxycycline (Option B):** It is a slow-acting blood schizonticide used as an **adjunct** to Quinine to ensure complete parasite clearance and prevent recrudescence. **High-Yield Clinical Pearls for NEET-PG:** 1. **First-line for CRPV:** ACT (e.g., Artesunate + Lumefantrine) is preferred. 2. **Radical Cure:** Regardless of the drug used for blood schizonts, **Primaquine** (for 14 days) must be added to treat hypnozoites in the liver to prevent relapse in *P. vivax*. 3. **Tafenoquine:** A newer single-dose alternative to Primaquine for radical cure (requires G6PD screening). 4. **Mechanism of Chloroquine Resistance:** Primarily due to mutations in the **PvCRT-o** gene (ortholog to PfCRT) or **PvMDR1** gene.
Explanation: The World Health Organization (WHO) recommends **Artemisinin-based Combination Therapies (ACTs)** as the first-line treatment for uncomplicated *P. falciparum* malaria [1, 2]. The rationale behind ACT is to combine a fast-acting artemisinin derivative (to rapidly reduce parasite biomass) with a long-acting partner drug (to eliminate remaining parasites and prevent resistance) [1, 2]. Monotherapy for the treatment of uncomplicated malaria is strongly discouraged to prevent the selection of artemisinin-resistant parasites [2]. **Why Option B is the Correct Answer:** **Artesunate plus Quinine** is not a recommended ACT. Quinine has a short half-life (approx. 10–12 hours) and requires frequent dosing (thrice daily for 7 days). A true ACT requires a **long-acting partner drug** to provide a "sustained tail" of protection. Furthermore, quinine is typically reserved for severe malaria (IV) or as a second-line oral agent when ACTs fail, but it is not used as a standard "combination partner" in the ACT framework. **Analysis of Incorrect Options:** * **Option A (Artemether + Lumefantrine):** This is the most widely used fixed-dose ACT globally (Coartem) [2, 3]. Lumefantrine has a long half-life (3–6 days), making it an ideal partner. * **Option C (Artesunate + Sulfadoxine-Pyrimethamine):** A recommended ACT, though its use is declining in areas with high high-level SP resistance. * **Option D (Artesunate + Mefloquine):** A highly effective ACT, commonly used in Southeast Asia and South America where mefloquine resistance is not predominant [3]. **High-Yield Clinical Pearls for NEET-PG:** * **WHO-approved ACTs:** Other combinations include Artesunate + Amodiaquine and Dihydroartemisinin + Piperaquine. * **Severe Malaria:** The drug of choice is **IV Artesunate** (preferred over IV Quinine). * **Pregnancy:** ACTs are now recommended by the WHO for treating uncomplicated malaria in **all trimesters**, including the first trimester. * **Mechanism:** Artemisinins act by releasing free radicals via the cleavage of their endoperoxide bridge by parasite heme.
Explanation: **Explanation:** The primary goal of antibiotic prophylaxis in dentistry is to prevent **Infective Endocarditis (IE)** in high-risk patients. Prophylaxis is indicated for procedures that involve significant manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa, as these actions are likely to cause transient bacteremia. **1. Why Option A is Correct:** **Making of impressions** is considered a non-invasive procedure. It does not involve trauma to the gingiva or mucosal bleeding. According to the **American Heart Association (AHA)** and **NICE guidelines**, non-manipulative procedures such as taking impressions, routine radiographs, and placement of removable appliances do not require antibiotic prophylaxis because the risk of bacteremia is negligible. **2. Why the Other Options are Incorrect:** * **Dental extraction (B):** This is a high-risk procedure involving significant trauma to the alveolar bone and gingiva, leading to predictable bacteremia. * **Replantation of tooth (C):** This involves manipulation of the periodontal ligament and periapical tissues, necessitating prophylaxis in susceptible patients. * **Gingivectomy (D):** Any periodontal surgery involving the gingival margin is highly associated with the entry of oral flora (like *Viridans group streptococci*) into the bloodstream. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Oral **Amoxicillin (2g)** given 30–60 minutes before the procedure. * **If Penicillin allergic:** Clindamycin (600mg), Cephalexin (2g), or Azithromycin/Clarithromycin (500mg). * **High-risk conditions requiring prophylaxis:** Prosthetic heart valves, prior history of IE, Cyanotic Congenital Heart Disease (unrepaired), and Cardiac transplant recipients with valve regurgitation. * **Not recommended for:** Mitral valve prolapse (without regurgitation), Rheumatic heart disease (per latest AHA updates), or routine anesthetic injections through non-infected tissue.
Explanation: **Explanation:** **Efavirenz** (often referred to as Eirenz in some contexts) is a potent **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)**. It works by binding directly and non-competitively to the HIV-1 reverse transcriptase enzyme at a site distinct from the active site (the NNRTI pocket). This induces a conformational change that inhibits the enzyme's ability to convert viral RNA into DNA, thereby halting viral replication. **Analysis of Options:** * **Option B (Correct):** Efavirenz is a classic NNRTI. Unlike Nucleoside RTIs (NRTIs), it does not require intracellular phosphorylation to become active. * **Option A (Incorrect):** Protease Inhibitors (e.g., Ritonavir, Atazanavir) act at the final stage of the viral life cycle by preventing the cleavage of precursor polyproteins, resulting in the production of immature, non-infectious virions. * **Option C (Incorrect):** Integrase Strand Transfer Inhibitors (INSTIs) (e.g., Raltegravir, Dolutegravir) prevent the integration of the viral DNA into the host cell genome. * **Option D (Incorrect):** Entry inhibitors include Fusion inhibitors (Enfuvirtide) and CCR5 antagonists (Maraviroc), which prevent the virus from attaching to or entering the CD4+ cell. **High-Yield Clinical Pearls for NEET-PG:** * **CNS Side Effects:** Efavirenz is notorious for causing neuropsychiatric symptoms, including vivid dreams, nightmares, dizziness, and "hangover" sensations. * **Teratogenicity:** It was traditionally avoided in the first trimester of pregnancy due to a potential risk of neural tube defects (though recent guidelines have relaxed this). * **Administration:** It should be taken on an **empty stomach** (preferably at bedtime) to reduce CNS side effects, as high-fat meals increase its absorption and toxicity. * **Resistance:** NNRTIs have a low genetic barrier to resistance; a single mutation (K103N) can lead to high-level cross-resistance across the class.
Explanation: **Explanation:** **1. Why Griseofulvin is Correct:** Griseofulvin is an antifungal agent used for dermatophytosis. It is well-known to cause a **disulfiram-like reaction** when consumed with alcohol. This occurs because the drug interferes with the enzyme **aldehyde dehydrogenase**, leading to the accumulation of acetaldehyde in the blood. Clinical symptoms include flushing, tachycardia, palpitations, nausea, and hypotension. **2. Why the Other Options are Incorrect:** * **Amphotericin B:** This is a polyene antifungal known for its significant nephrotoxicity and infusion-related reactions ("shake and bake" chills/fever), but it does not interact with alcohol via the disulfiram pathway. * **Terbinafine:** An allylamine used for onychomycosis. Its primary side effects are gastrointestinal upset and hepatotoxicity; it does not cause disulfiram-like reactions. * **Rifampicin:** An antitubercular drug and a potent **microsomal enzyme inducer**. While it is hepatotoxic, it does not inhibit aldehyde dehydrogenase. **3. NEET-PG High-Yield Pearls:** To excel in NEET-PG, remember the mnemonic **"PM G C"** for common drugs causing disulfiram-like reactions: * **P:** Procarbazine * **M:** Metronidazole (Most common MCQ answer), Moxalactam * **G:** **Griseofulvin** * **C:** Cefoperazone, Cefotetan, Chlorpropamide (1st gen Sulfonylurea) **Additional Fact:** Griseofulvin is a **microsomal enzyme inducer** (unlike most antifungals which are inhibitors) and its absorption is significantly increased when taken with a **fatty meal**.
Explanation: **Explanation:** The correct answer is **Thalidomide**. **Why Thalidomide is correct:** Lepra reactions are immunologically mediated inflammatory episodes occurring during the course of leprosy. **Type 2 Lepra Reaction (Erythema Nodosum Leprosum - ENL)** is a Type III hypersensitivity reaction characterized by painful nodules, fever, and systemic symptoms. While systemic corticosteroids are the first-line treatment, **Thalidomide** is the drug of choice for **steroid-resistant or steroid-dependent ENL**. Its efficacy is attributed to its potent inhibition of **Tumor Necrosis Factor-alpha (TNF-α)** and its ability to modulate T-cell responses. **Why other options are incorrect:** * **Clofazimine:** While it has anti-inflammatory properties and is used to prevent recurrences of ENL, it is slower acting than Thalidomide and is primarily used as part of Multi-Drug Therapy (MDT) or as a steroid-sparing agent. * **Dapsone & Rifampicin:** These are bactericidal/bacteriostatic components of MDT used to kill *Mycobacterium leprae*. They do not have significant acute anti-inflammatory properties and, in some cases, the initiation of these drugs can actually trigger a lepra reaction due to the release of antigens from dying bacilli. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Thalidomide:** TNF-α inhibitor. * **Teratogenicity:** Thalidomide is famous for causing **Phocomelia** (seal-like limbs). It is strictly contraindicated in pregnancy and requires the "S.T.E.P.S." program for risk management. * **Type 1 Reaction:** A Type IV hypersensitivity (Reversal reaction); managed primarily with steroids, NOT Thalidomide. * **Drug of Choice for ENL:** Mild (NSAIDs), Severe (Steroids), Steroid-resistant (Thalidomide).
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free